Researchers compared SARS-CoV-2 Omicron variant of concern replication in human cell lines and primary airway cultures and measured host responses to infection.
H1 2023 RESULTS – Major advances in clinical programs – Extension of cash horizon to February 2024 – Biotech Investments
EQS-News: Affluent Medical SA / Key word(s): Half Year Results Affluent Medical SA: H1 2023 RESULTS – Major advances in clinical programs – Extension of